Testosterone preparations for clinical use in males

Testosterone: Action, Deficiency, Substitution, Fourth Edition

Volumn , Issue , 2012, Pages 309-335

  Behre, Hermann M ^a   Nieschlag, Eberhard ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866443683     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139003353.016     Document Type: Chapter

References (114)

1. Aakvaag A Stromme SB (1974) The effect of mesterolone administration to normal men on the pituitarytesticular function. Acta Endocrinol 77:380-386
2. Alkalay D Khemani L Wagner WE Bartlett MF (1973) Sublingual and oral administration of methyltestosterone. A comparison of drug bioavailability. J Clin Pharmacol New Drugs 13:142-151
3. Amory JK Anawalt BD Blaskovich PD Gilchriest J Nuwayser ES Matsumoto AM (2002) Testosterone release from a subcutaneous biodegradable microcapsule formulation (Viatrel) in hypogonadal men. J Androl 23:84-91
4. Amory JK Bush MA Zhi H Caricofe RB Matsumoto AM Swerdloff RS Wang C Clark RV (2011) Oral testosterone with and without concomitant inhibition of 5a-reductase by dutasteride in hypogonadal men for 28 days.J Urol 185:626-632
5. Anderson RA Wu FC (1996) Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J Clin Endocrinol Metab 81:896-901
6. Anderson RA Zhu H Cheng L Baird DT (2002) Investigation of a novelpreparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants. Contraception 66:357-364
7. Anonymous (1988) Methyltestosteron- Monographie. Bundesanzeiger 40:5140-5141
8. Bagchus WM Hust R Maris F Schnabel PG Houwing NS (2003) Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 23:319-325
9. Bals-Pratsch M Knuth UA Yoon YD Nieschlag E (1986) Transdermal testosterone substitution therapy for male hypogonadism. Lancet 2:943-946
10. Bals-Pratsch M Langer K Place VA Nieschlag E (1988) Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol (Copenh) 118:7-13
11. Behre HM Nieschlag E (1992) Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 75:1204-1210
12. Behre HM Baus S Kliesch S Keck C Simoni M Nieschlag E (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80:2394-2403
13. Behre HM Abshagen K Oettel M Hubler D Nieschlag E (1999a) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140:414-419
14. Behre HM von Eckardstein S Kliesch S Nieschlag E (1999b) Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clin Endocrinol (Oxf) 50:629-635
15. Bhasin S Swerdloff RS Steiner B Peterson MA Meridores T Galmirini M Pandian MR Goldberg R Berman N (1992) A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab 74:75-83
16. Boyd PR Mark GJ (1977) Multiple hepatic adenomas and a heptatocellular carcinoma in a man on oral methyl testosterone for eleven years. Cancer 40: 1765-1770
17. Breuer H Gütgemann D (1966) Wirkung von 1alpha-Methyl- 5alpha-androstan-17b-ol-3-on (Mesterolon) auf die Steroidausscheidung beim Menschen. Arzneimittelforschung 16:759-762
18. Brocks DR Meikle AW Boike SC Mazer NA Zariffa N Audet PR Jorkasky DK (1996) Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. J Clin Pharmacol 36:732-739
19. Burris AS Ewing LL Sherins RJ (1988) Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertil Steril 50:493-497
20. Carbone JV Grodsky GM Hjelte V (1959) Effect of hepatic dysfunction on circulating levels of sulphobromopthalein and its metabolites. J Clin Invest 38:1989-1996
21. Coert A Geelen J de Visser J van der Vies J (1975) The pharmacology and metabolism of testosterone undecanoate (TU) a new orally active androgen. Acta Endocrinol 79:789-800
22. Crabbé P Diczfalusy E Djerassi C (1980) Injectable contraceptive synthesis: an example of international cooperation. Science 209:992-994
23. Cunningham GR Silverman VE Kohler PO (1978) Clinical evaluation of testosterone enanthate for induction and maintenance of reversible azoospermia in man. In: Patanelli DJ (ed) Hormonal Control of Male Fertility (Workshop Proceedings) NIH Publication No. 78-1097. US Department of Health Education and Welfare (NIH) Bethesda MD pp 71-87
24. Danner C Frick G (1980) Androgen substitution with testosteronecontaining nasal drops. Int J Androl 3:429-431
25. Deanesly R Parkes AS (1938) Further experiments on the administration of hormones by the subcutaneous implantation of tablets. Lancet 232: 606-608
26. de Lorimer AA Gordan GS Löwe RC Carbone JV (1965) Methyltestosterone: related steroids and liver function. Arch Intern Med 116:289-294
27. Dobs A McGettigan J Norwood P Potts S Gould E (2011) Baseline body mass index (BMI) has no effect upon normalization of testosterone concentrations with testosterone 2% gel [abstract]. Endocr Rev 32 (03_MeetingAbstracts):P1-353
28. Escamilla RF (1949) Treatment of preadolescent eunuchoidism with (methyl)testosterone linguets. Amer Pract 3:425
29. Falk H Thomas LB Popper H Ishak KG (1979) Hepatic angiosarcoma associated with androgenic-anabolic steroids. Lancet 2:1120-1123
30. Farrell GC Joshua DE Uren RF Baird PJ Perkins KW Kronenberg H (1975) Androgen-induced hepatoma. Lancet 1:430-432
31. Feldmann RJ Maibach HI (1967) Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 48:181-183
32. Fennell C Sartorius G Ly LP Turner L Liu PY Conway AJ Handelsman DJ (2010) Randomized cross-over clinical trial of injectablevs. Implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol (Oxf) 73:102-109
33. Findlay JC Place VA Snyder PJ (1987) Transdermal delivery of testosterone. J Clin Endocrinol Metab 64:266-268
34. Frey H Aakvaag A Saanum D Falch J (1979) Bioavailability of oral testosterone in males. Eur J Clin Pharmacol 16:345-349
35. Fujioka M Shinohara Y Baba S Irie M Inoue K (1986) Pharmacokinetic properties of testosterone propionate in normal men. J Clin Endocrinol Metab 63:1361-1364
36. Fukutani K Isurugi K Takayasu H Wakabayashi K Tamaoki B-I (1974)Effects of depot testosterone therapy on serum levels of luteinizing hormone and folliclestimulating hormone in patients with Klinefelter's syndrome and hypogonadotropic eunuchoidism. J Clin Endocrinol Metab 39:856-864
37. Gerhards E Gibian H Kolb KH (1966) Zum Stoffwechsel von 1alpha- Methyl-5alpha androstan-17b-ol-3- on (Mesterolon) beim Menschen.Arneimittelforschung 16:458-463
38. Goodman MA Laden AMJ (1977) Hepatocellular carcinoma in association with androgen therapy. Med J Aust 1:220-221
39. Gordon RD Thomas MJ Poyntin JMStocks AE (1975) Effect of mesterolone on plasma LH FSH and testosterone. Andrologia 7:287-296
40. Gu YQ Wang XH Xu D Peng L Cheng LF Huang MK Huang ZJ ZhangGY (2003) A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinesemen. J Clin Endocrinol Metab 88:562-568
41. Hamburger C (1958) Testosterone treatment and 17-ketosteroid excretion. Acta Endocrinol 28:529-536
42. Handelsman DJ Conway AJ Boylan LM (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 70:216-222
43. Handelsman DJ Mackey MA Howe C Turner L Conway AJ (1997) Analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol 47:311-316
44. Heywood R Hunter B Green OP Kennedy SJ (1977a) The toxicity of methyl testosterone in the rat. Toxicol Lett 1:27-31
45. Heywood R Chesterman H Ball SA Wadsworth PF (1977b) Toxicity of methyl testosterone in the beagle dog. Toxicology 7:357-365
46. Horst HJ Höltge WJ Dennis M Coert A Geelen J Voigt KD (1976) Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wschr 54:875-879
47. Jockenhövel F Vogel E Kreutzer E Reinhard W Lederbogen S Reinwein D (1996) Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal man. Clin Endocrinol 45:61-71
48. Johnsen SG Bennet EP Jensen VG (1974) Therapeutic effectiveness of oral testosterone. Lancet 2: 1473-1475
49. Johnsen SG Kampmann JP Bennet EP Jörgensen F (1976) Enzyme induction by oral testosterone. Clin Pharmacol Ther 20:233-237
50. Jones TH Arver S Behre HM Buvat J Meuleman E Moncada I Morales AM Volterrani M Yellowlees A Howell JD Channer KS; TIMES2 Investigators (2011) Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34:828-837
51. Jordan WP (1997) Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am J Contact Dermat 8:108-113
52. Junkmann K (1952) Über protrahiert wirksame Androgene. Arch Path Pharmacol 215:85-92
53. Junkmann K (1957) Long-acting steroids in reproduction. Recent Prog Horm Res 13:389-419
54. Kaminetsky JC Moclair B Hemani MSand M (2011) A phase IVprospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism.Sex Med 8:1186-1196
55. Kaufman JM Miller MG Garwin JL Fitzpatrick S McWhirter C Brennan JJ (2011) Efficacy and safety study of 1.62% testosteronegel for the treatment of hypogonadal men. J Sex Med 8:2079-2089
56. Kelleher S Conway AJ Handelsman DJ (1999) A randomized controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate. Eur J Endocrinol 146:513-518
57. Kelleher S Conway AJ Handelsman DJ (2001) Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol (Oxf) 55:531-536
58. Khera M Bhattacharya RK Blick G H Nguyen D Miner MM (2011) Improved sexual function with testosterone replacement therapy in hypogonadal men: realworld data from the Testim Registry in the United States (TRiUS). J Sex Med 8:3204-3213
59. Korenman SG Viosca S Garza D M Place V Campbell P Davis SS (1987) Androgen therapy of hypogonadal men with transscrotal testosterone system. Am J Med 83:471-478
60. Krüskemper HI Noell G (1967) Steroidstruktur und Lebertoxizität. Acta Endocrinol 54:73-80
61. Kühnert B Byrne M Simoni M Köpcke W Gerss J Lemmnitz G Nieschlag E (2005) Testosterone substitution with a new transdermal hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol 153:317-326
62. Lee A Rubinow K Clark RV Caricofe RB Bush MA Zhi H Roth MY Page ST Bremner WJ Amory JK (2011) Pharmacokinetics of modifiedslow-release oral testosterone over nine days innormal men with experimental hypogonadism. J Androl Aug 25 [Epub ahead of print]
63. Mackey MA Conway AJ Handelsman DJ (1995) Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod 10:862-865
64. Maisey NM Bingham J Marks V English J Chakraborty J (1981) Clinical efficacy of testosterone undecanoate in male hypogonadism. Clin Endocrinol 14:625-629
65. Mattern C Hoffmann C Morley JE Badiu C (2008) Testosterone supplementation for hypogonadal men by the nasal route. Aging Male 11:171-178
66. McNicholas TA Dean JD Mulder H Carnegie C Jones NA (2003) A novel testosterone gel formulation normalizes androgen levels in hypogonadal men with improvements in body composition and sexual function. BJU Int 91:69-74
67. Meikle AW Arver S Dobs AS Sanders SW Rajaram L Mazer N (1996) Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site - a clinical research center study. J Clin Endocrinol Metab 81:1832-1840
68. Minto CF Howe C Wishart S Conway AJ Handelsman DJ (1997). Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester injection site and injection volume. J Pharmacol Exp Ther 281:93-102
69. Nankin HR (1987) Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril 47:1004-1009
70. Nieschlag E (1981) Ist die Anwendung von Methyltestosteron obsolet? Dtsch med Wschr 106:1123-1125
71. Nieschlag E Mauss J Coert A Kicovic P (1975) Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol 79:366-374
72. Nieschlag E Cüppers HJ Wiegelmann W Wickings EJ (1976) Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 7:138-145
73. Nieschlag E Cüppers EJ Wickings EJ (1977) Influence of sex testicular development and liver function on the bioavailability of oral testosterone. Europ J Clin Invest 7:145-147
74. Nieschlag E Büchter D von Eckardstein S Abshagen K Simoni M BehreHM (1999) Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 51:757-763
75. Paradinas FJ Bull TB Westaby D Murray-Lyon IM (1977) Hyperplasia and prolapse of hepatocytes into hepatic veins during longterm methyltestosterone therapy: possible relationships of these changes to the development of peliosis hepatis and liver tumours. Histopathology 1:225-246
76. Parker S Armitage M (1999) Experience with transdermal testosterone replacement therapy for hypogonadal men. Clin Endocrinol (Oxf) 50:57-62
77. Pitha J Harman SM Michel ME (1986) Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones. J Pharm Sci 75:165-167
78. Raynaud JP Aumonier C Gualano V Betea D Beckers A (2008a) Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. J Steroid Biochem Mol Biol 109:177-184
79. Raynaud JP Legros JJ Rollet J Augès M Bunouf P Sournac M Fiet J (2008b) Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men. J Steroid Biochem Mol Biol 109:168-176
80. Raynaud JP Augès M Liorzou L Turlier V Lauze C (2009) Adhesiveness of a new testosteronein- adhesive matrix patch after extreme conditions. Int J Pharm 375:28-32
81. Rolf C Kemper S Lemmnitz G Eickenberg U Nieschlag E (2002a) Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normalmen. Eur J Endocrinol 146:673-679
82. Rolf C Knie U Lemmnitz G Nieschlag E (2002b) Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol (Oxf) 56:637-641
83. Ruzicka L Goldberg MW Rosenberg HR (1935) Herstellung des 17- Methyl-testosterons und anderer Androsten- und Androstanderivate. Zusammenhänge zwischen chemischer Konstitution und männlicher Hormonwirkung. Helv Chim Acta 18:1487-1498
84. Salehian B Wang C Alexander G Davidson T McDonald V Berman N Dudley RE Ziel F Swerdloff RS (1995) Pharmacokinetics bioefficacy and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate - a clinical research center study. J Clin Endocrinol Metab 80:3567-3575
85. Schnabel PG Bagchus W Lass HThomsen T Geurts TB (2007) The effect of food composition on serumtestosterone levels after oral administration of Andriol Testocaps. Clin Endocrinol (Oxf) 66:579-585
86. Schulte-Beerbühl M Nieschlag E (1980) Comparison of testosterone dihydrotestosterone luteinizing hormone and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril 33:201-203
87. Schürmeyer T Nieschlag E (1984) Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. Int J Androl 7:181-187
88. Schürmeyer T Wickings EJ Freischem CW Nieschlag E (1983) Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrino 102:456-462
89. Shackleford DM Faassen WA Houwing N Lass H Edwards GA Porter CJ Charman WN (2003) Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two Andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther 306:925-933
90. Snyder CN Clark RV Caricofe RB Bush MA Roth MY Page ST Bremner WJ Amory JK (2010) Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism.J Androl 31: 527-535
91. Snyder PJ Lawrence DA (1980) Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 51:1335-1339
92. Sokol RZ Swerdloff RS (1986) Practical considerations in the use of androgen therapy. In: Santen JR Swerdloff RS (eds) Male Reproductive Dysfunction. Marcel Dekker New York pp 211-225
93. Steidle C Schwartz S Jacoby K Sebree T Smith T Bachand R; North American AA2500 T Gel Study Group (2003) AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88:2673- 2681
94. Stuenkel CA Dudley RE Yen SC (1991) Sublingual administration of testosterone hydroxypropyl-bcyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J Clin Endocrinol Metab 72:1054-1059
95. Swerdloff RS Wang C Cunningham G Dobs A Iranmanesh A Matsumoto AM Snyder PJ Weber T Longstreth J Berman N (2000) Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 85:4500-4510
96. van der Vies J (1965) On the mechanism of action of nandrolone phenylpropionate and nandrolone decanoate in rats. Acta Endocrinol 49:271-282
97. van der Vies J (1970) Model studies in vitro with long-acting hormonal preparations. Acta Endocrinol 64:656-669
98. van der Vies J (1985) Implications of basic pharmacology in the therapy with esters of nandrolone. Acta Endocrinol Suppl (Copenh) 271:38-44
99. Vest SA Howard JE (1939) Clinical experiments with androgens. IV: a method of implantation of crystalline testosterone. J Am Med Assoc 113:1869-1872
100. von Eckardstein S Nieschlag E (2002) Treatment of male hypogonadismwith testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23:419-425
101. Wang C Eyre R Clark D Kleinberg C Newman I Iranmanesh A Veldhuis R Dudley RE Berman N Davidson T Barstow TS Sinow R Alexander G Swerdloff R (1996) Sublingual testosterone replacement improves muscle mass and strength decreases bone resorption and increases bone formation markers in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 81:3654-3662
102. Wang C Berman N Longstreth JA Chuapoco B Hull L Steiner B Faulkner S Dudley RE Swerdloff RS (2000) Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a general clinical research center study. J Clin Endocrinol Metab 85:964-969
103. Wang C Swerdloff R Kipnes M Matsumoto AM Dobs AS Cunningham G Katznelson L Weber TJ Friedman TC Snyder P Levine HL (2004) New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 89:3821-3829
104. Wang C Ilani N Arver S McLachlan RI Soulis T Watkinson A (2011) Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf) 75:836-843
105. Wang L Shi DC Lu SY Fang RY (1991) The therapeutic effect of domestically produced testosterone undecanoate in Klinefelter syndrome. New Drugs Mark 8:28-32
106. Werner SC Hamger FM Kritzler RA (1950) Jaundice during methyltestosterone therapy. Am J Med 8:325-331
107. Westaby D Ogle SJ Paradinas FJ Randell JB Murray-Lyon IM (1977) Liver damage from long-term methyltestosterone. Lancet 2:261-263
108. World Health Organization Nieschlag E Wang C Handelsman DJ Swerdloff RS Wu F Einer-Jensen N Waites G (1992) Guidelines for the Use of Androgens. WHO Geneva
109. Wu FCW Farley TMM Peregoudov A Waites GMH (1996) Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 65:626-636
110. Yin AY Htun M Swerdloff RS Diaz- Arjonilla M Dudley RE Faulkner SBross R Leung A Baravarian S Hull L Longstreth JA Kulback S Flippo G Wang C (2012) Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a ne selfemulsifying formulation. J Androl 33:190-201
111. Zhang GY Gu YQ Wang XH Cui YG Bremner WJ (1998) A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 19:761-768
112. Zitzmann M (2009) Pharmacogenetics of testosterone replacement therapy. Pharmacogenomics 10:1341-1349
113. Zitzmann M Nieschlag E (2007) Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 92:3844-3853
114. Zitzmann M Hanisch JU Mattern A Maggi M (2011) Testosterone replacement therapy in male hypogonadism: Final results from the largest international substitution trial involving 1493 patients [abstract]. Endocr Rev 32 (03_MeetingAbstracts):P1-347